Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 263.55B P/E 35.15 EPS this Y 1.20% Ern Qtrly Grth 472.80%
Income 5.95B Forward P/E 13.52 EPS next Y 7.30% 50D Avg Chg 8.00%
Sales 54.4B PEG 2.43 EPS past 5Y 5.57% 200D Avg Chg -1.00%
Dividend 4.00% Price/Book 19.85 EPS next 5Y 6.21% 52W High Chg -11.00%
Recommedations 2.20 Quick Ratio 0.72 Shares Outstanding 1.77B 52W Low Chg 14.00%
Insider Own 0.11% ROA 7.71% Shares Float 1.76B Beta 0.58
Inst Own 72.75% ROE 56.24% Shares Shorted/Prior 15.93M/13.54M Price 149.38
Gross Margin 69.17% Profit Margin 11.02% Avg. Volume 5,937,400 Target Price 183.88
Oper. Margin 28.29% Earnings Date Jul 25 Volume 5,753,546 Change 0.57%
About AbbVie Inc.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc. News
10:45 AM Why AbbVie (ABBV) is a Great Dividend Stock Right Now
08:50 AM Here's Why AbbVie (ABBV) is a Strong Momentum Stock
07:45 AM AbbVie's (ABBV) Skyrizi Gets FDA Nod for Ulcerative Colitis
03:19 AM 2 Super Smart Dividend Stocks to Buy With $10,000 Right Now
03:12 AM AbbVie’s SKYRIZI gains US FDA approval for ulcerative colitis
06/18/24 U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
06/18/24 AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider
06/18/24 Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
06/18/24 Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
06/18/24 Humira: the highs and lows of the world’s best-selling drug
06/16/24 2 Dividend Stocks That Could Pay You for Life
06/14/24 AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
06/14/24 Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
06/14/24 AbbVie (ABBV) Buys Global Rights to Novel IBD Candidate
06/14/24 AbbVie joins in latest gastrointestinal drug chase
06/14/24 AbbVie and FutureGen link on inflammatory bowel disease
06/13/24 Here's How Many Shares Of AbbVie You Would Need To Earn $500 Per Month In Dividends
06/13/24 AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease
06/12/24 Blue-Chip Bonanzas: 3 Industry Leaders Trading at Unbelievable Discounts
06/12/24 AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
ABBV Chatroom

User Image Iceman467 Posted - 28 minutes ago

$ABBV nice approval post market yesterday Skyrizi

User Image TalkMarkets Posted - 12 hours ago

Earn Income While Playing The Hottest Sectors $AVGO $MSFT $ABBV https://talkmarkets.com/content/stocks--equities/earn-income-while-playing-the-hottest-sectors?post=450812

User Image MakePeaceWithMyself Posted - 16 hours ago

$ABBV sucks crap 💩

User Image DonCorleone77 Posted - 17 hours ago

$ABBV AbbVie: FDA approves SKYRIZI for ulcerative colitis AbbVie announced the U.S. FDA has approved SKYRIZI for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.3 SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases.

User Image MontanaT Posted - 18 hours ago

$ABBV I love AbbVie ❤️

User Image Stock_Titan Posted - 20 hours ago

$ABBV U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease https://www.stocktitan.net/news/ABBV/u-s-fda-approves-skyrizi-r-risankizumab-rzaa-for-ulcerative-colitis-syarrskqaohm.html

User Image DDGenie Posted - 1 day ago

$SLS In the Nov. '22 trial revision, the only time the public has received information regarding the trial's data, the combined (active+control) data showed an overall survival that was "approximately two-fold" the expected value. If this was a result of the control exceeding expectations, the trial would have been stopped for futility. However, 6 affirmations of efficacy later, the trial remains active and continues to exceed expectations for the timing of events, even after reducing the # of events for analyses by -25%. In the Ph.2 trial, the drug under study (ie. GPS) quadrupled the overall survival of the control arm (21.0 v. 5.4, p-val <0.02). It would appear that GPS is once again exceeding expectations, otherwise the trial would have almost certainly been halted for futility by now (six times they've confirmed efficacy). $XBI $MRK $ABBV $BMY

User Image DDGenie Posted - 1 day ago

$SLS Yesterday, the data cmte. for the Phase 3 REGAL trial (n.b. active 41mos.) affirmed the efficacy & safety of the trial for the 6th time; however, the purpose of this meeting was to check if the trial had reached the 60th event threshold for triggering the interim analysis. The data cmte. met in late April to review the fully enrolled trial data and provided their 5th efficacy/safety analysis at that time and stated in the 4/29 PR that they scheduled ad hoc for ~2mos. later to review event data. Each of the five previous data cmte. meetings were 4mos. apart. Now, for the first time in >40mos. of trial activity, the data cmte. has provided a forecast on the interim analysis stating that they're extremely confident that it will occur "by Q4". The timing to events exceeding expectations is reminiscent of the Nov. '22 REGAL protocol revisions, where the # of events required for analyses were reduced by -25% b/c patients lived much longer than expected. $XBI $ABBV $MRK $BMY

User Image Iceman467 Posted - 1 day ago

$ABBV Piper nice upgrade today. Price target $190

User Image JFDI Posted - 1 day ago

$ABBV breaking out.

User Image Bigjim00 Posted - 1 day ago

$ABBV LFG

User Image MontanaT Posted - 1 day ago

$ABBV AbbVie beast

User Image DDGenie Posted - 2 days ago

$SLS Data Cmte. for Ph.3 REGAL affirmed their 6th efficacy & safety analysis this morning. For the first time, the Data Cmte. announced their expectations for Interim Analysis "by Q4". REGAL is currently in its 41st month. In Ph.2, GPS quadrupled the control's longevity in the same patient setting (n.b. 21.0mos. v. 5.4mos, p-val <0.02). $XBI $ABBV $MRK $BMY

User Image cb5000calls Posted - 2 days ago

$SLS this was as much a message for shareholders as it was for the potential buyers aka $MRK $BMY $ABBV Label Expansion is next because GPS is amazing!!! “What makes me equally and perhaps even more excited is that now with the REGAL study enrollment completed and upcoming efficacy read-out, I am looking forward to the potential expansion of GPS into other settings, beyond maintenance of second remissions in patients with AML, as it could function as a treatment modality in patients in first remission as well as post bone marrow transplant.” Said Panagiotis Tsirigotis, MD, Professor of Medicine at the University of Athens and Chief of Leukemia at Attikon University Hospital. https://ir.sellaslifesciences.com/news/News-Details/2024/SELLAS-Life-Sciences-Announces-Positive-Recommendation-from-the-Independent-Data-Monitoring-Committee-of-the-Phase-3-REGAL-Trial-in-Acute-Myeloid-Leukemia/default.aspx

User Image FranciscoJavier2 Posted - 2 days ago

Investigating $ABBV (AbbVie Inc.), I found that its focus on pharmaceuticals, innovative treatments, and strong dividend payments are key strengths. Seeking Alpha highlights AbbVie’s strategic initiatives in expanding its pharmaceutical portfolio and enhancing its research capabilities as key factors for its market position. Navigating the Finviz dashboard can be overwhelming with its numerous KPIs. To streamline my search for promising companies, I use the GPT called "Finviz Strategy Advisor" from the GPT Store on OpenAI. This tool is free for everyone using ChatGPT 4.0 Plus. I highly recommend giving it a try, investor. The Finviz Strategy Advisor chatbot is designed to generate a Finviz URL with KPI settings tailored to your investment style, whether you are a value investor, dividend seeker or other type of investor. All you have to do is copy the URL provided by the chatbot into your browser, and the settings will be set for you. It's more efficient. https://chatgpt.com/g/g-hpr8yufoJ-finviz-strategy-advisor

User Image DefenseMania Posted - 3 days ago

$AMGN $LLY $PFE $ABBV https://www.investors.com/news/technology/gilead-stock-weight-loss-drug/?src=A00220&yptr=yahoo

User Image DonCorleone77 Posted - 4 days ago

$ABBV AbbVie recommends shareholders reject Tutanota's 'mini-tender' offer AbbVie has been notified that Tutanota LLC has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purchase up to 250,000 shares of AbbVie common stock at $165.00 per share in cash. This offer is conditioned on, among other things, the closing price per share of AbbVie's common stock exceeding the Offer Price on the last full trading day prior to the expiration date of the offer. Tutanota also states in its offer documents that it expects to extend the offer for successive periods of 45 to 180 days until the market price of AbbVie's common stock exceeds the Offer Price. This means that AbbVie shareholders who tender their shares in the offer will receive a below-market price if the offer conditions are satisfied and their shares are accepted in the offer. There is no guarantee that the conditions of the offer will be satisfied. AbbVie does not endorse Tutanota's offer and is not associated in any way with Tutanota, its offer, or the offer documents. AbbVie recommends that AbbVie shareholders do not tender their shares in response to this unsolicited offer. AbbVie shareholders who have already tendered may withdraw their shares by providing the written notice described in the Tutanota offer documents prior to the expiration of the offer, which is currently scheduled at 5:00 p.m. New York City time on June 28, 2024.

User Image FranciscoJavier2 Posted - 4 days ago

Exploring $ABBV (AbbVie Inc.), I noted that its focus on biopharmaceuticals and consistent dividend growth make it an attractive investment. InvestorPlace discusses AbbVie’s strategic acquisitions and its strong product pipeline in immunology and oncology as key drivers for its market position. The Finviz dashboard offers a plethora of KPIs, which can be daunting. To simplify my search for promising companies, I rely on the GPT called "Finviz Strategy Advisor" from the GPT Store on OpenAI. This tool is available for free with ChatGPT 4.0 Plus. I encourage you to try it out, investor. The Finviz Strategy Advisor chatbot is designed to generate a Finviz URL with KPI settings tailored to your investment style, whether you are a value investor, dividend seeker or other type of investor. All you have to do is copy the URL provided by the chatbot into your browser, and the settings will be set for you. It's more efficient. https://chatgpt.com/g/g-hpr8yufoJ-finviz-strategy-advisor

User Image JFDI Posted - 5 days ago

$ABBV alerts at 171

User Image SilentSuccess Posted - 5 days ago

$ABBV Got out with a meager 11% gain.

User Image ssly800 Posted - 5 days ago

$ABBV long long hold. See ya in 5 years. …

User Image rickyspanish Posted - 5 days ago

$SPY Come on down $abbv ugly people can't buy Botox anymore.

User Image Greenclover Posted - 5 days ago

$ABBV just continue to add… it’ll pay off

User Image SilentSuccess Posted - 5 days ago

$ABBV June 21 puts

User Image JakeDelToro Posted - 6 days ago

$BMY $MRK $ABBV Bidding war for $SLS starts next week. Get your checkbooks.

User Image cea Posted - 6 days ago

$ABBV $BMY $MRK $SLS $XBI @DDGenie Multiply that 4.5 and you get market value for GPS for treatment of AML alone. If you consider other cancers - both blood and solid tumors - AND the value add to existing therapies market value life AND of SLS009…well the speculative potential is almost offensive.

User Image DDGenie Posted - 6 days ago

@JakeDelToro To your line of thinking Jake, I did find that FierceBio article which you shared to be intriguing. BMY CEO's comment at the Goldman Sachs HC conf.: “But with that in mind, as we look at opportunities, we’re focused on the therapeutic areas we’re in.” -- GPS has partnered with Opdivo in MPM trials and it's been established through their work with MRK's Keytruda that GPS compliments PD-L1 inhibitors quite well in difficult to treat ovarian cancer settings. GPS fits well with Key & Opdivo's use settings for MPM/Ovarian but then there's also Abbvie's Venetoclax, which GPS appears to dramatically outperform in the targeted AML therapy areas of CR2/CR1 and their secondary asset, SLS009, is currently in-trial w/ Venetoclax-based regimens for R/R AML patients. $MRK $BMY $ABBV all have reasons to be interested in GPS Ph.3 interim data. Source for BMY's CEO quote: https://www.fiercepharma.com/pharma/bms-chief-boerner-says-company-still-hungry-deals-after-spending-more-20b-ma-last-year

User Image DDGenie Posted - 6 days ago

$SLS is currently valued at ~4% of the annual TAM (ie. >$2B) for its Ph.3 drug trial indication. There are no therapies approved specifically for use in this trial setting and in the Ph.2 trial, the drug nearly quadrupled the control's overall survival on a p-value <0.02. Ph. 3 Trial active >40mos. and waiting on the interim analysis. Perhaps this month, as the trial's DMC announced ad hoc meeting for June following their late-April scheduled review. First time that's ever happened in trial's history. CCO in Sept. '22 identified a market opportunity of 8700 patients annually. While pricing for GPS hasn't been announced, CCO noted at the time a range of ~$131k - $541k for the therapies currently available for use in the trial's targeted setting. Remember, the PH.2 data from 2018 showed their drug outperforming all of the established competitors by ~300%. Learn more about SLS, 10pg. summary DD: https://duediligencegenie.com/wp-content/uploads/2024/05/Sellas-Life-Sciences-1.pdf $XBI Trial partners include: $BMY $ABBV $MRK

User Image DonCorleone77 Posted - 6 days ago

$ABBV AbbVie enters license agreement with FutureGen to develop IBD therapy AbbVie and FutureGen Biopharmaceutical announced a license agreement to develop FG-M701, a next generation TL1A antibody for the treatment of inflammatory bowel disease, or IBD, currently in preclinical development. AbbVie will receive an exclusive global license to develop, manufacture and commercialize FG-M701. FutureGen will receive $150M in upfront and near-term milestone payments and will be eligible to receive up to an additional $1.56B in clinical development, regulatory and commercial milestones, as well as tiered royalties up to low-double digits on net sales.

User Image Stock_Titan Posted - 6 days ago

$ABBV AbbVie and FutureGen Announce License Agreement to Develop Next-Generation Therapy for Inflammatory Bowel Disease https://www.stocktitan.net/news/ABBV/abb-vie-and-future-gen-announce-license-agreement-to-develop-next-dw4u4n042yk2.html

Analyst Ratings
Piper Sandler Overweight Jun 18, 24
HSBC Buy Jun 5, 24
Cantor Fitzgerald Overweight May 17, 24
Barclays Overweight Apr 29, 24
BMO Capital Outperform Apr 29, 24
Barclays Overweight Mar 27, 24
Guggenheim Buy Mar 22, 24
Truist Securities Buy Feb 6, 24
Raymond James Outperform Feb 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Donoghoe Nicholas EVP, CHIEF BUS/STRAT.. EVP, CHIEF BUS/STRAT OFFICER Dec 26 Sell 154.72 2,912 450,545 55,903 12/28/23
GONZALEZ RICHARD A CHAIRMAN OF THE BOAR.. CHAIRMAN OF THE BOARD AND CEO Jul 31 Sell 148.87 78,500 11,686,295 565,294 08/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Apr 17 Sell 161.84 7,499 1,213,638 35,330 04/19/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Sell 155 15,003 2,325,465 42,829 03/02/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 28 Option 93.5 15,003 1,402,780 57,832 03/02/23
Siatis Perry C EVP, GC AND SECRETAR.. EVP, GC AND SECRETARY Feb 28 Sell 153.22 12,135 1,859,325 10,377 03/02/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Sell 151.02 28,541 4,310,262 37,921 02/21/23
Strom Carrie C SVP & PRES GLOBAL AL.. SVP & PRES GLOBAL ALLERG AESTH Feb 16 Option 62.09 14,179 880,374 66,462 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Option 51.42 25,000 1,285,500 258,208 02/21/23
SALEKI-GERHARDT AZITA EVP, OPERATIONS EVP, OPERATIONS Feb 16 Sell 149.59 25,000 3,739,750 233,208 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Sell 151.02 15,321 2,313,777 62,679 02/21/23
Sorg Elaine K. SVP, US COMMERCIAL O.. SVP, US COMMERCIAL OPERATIONS Feb 16 Option 105.92 15,321 1,622,800 78,000 02/21/23
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Option 104.59 79,801 8,346,387 231,904 05/25/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 23 Sell 151.16 79,801 12,062,719 152,103 05/25/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Option 54.86 83,960 4,606,046 125,583 05/20/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer May 16 Sell 155 83,960 13,013,800 41,623 05/20/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Option 78.23 200,000 15,646,000 252,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 16 Sell 154.58 200,000 30,916,000 152,103 05/18/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Sell 151.2 300,000 45,360,000 152,103 05/10/22
SEVERINO MICHAEL Vice Chairman Vice Chairman May 06 Option 57.21 300,000 17,163,000 252,103 05/10/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Option 58.88 27,690 1,630,387 88,631 03/25/22
Stewart Jeffrey Ryan EVP, Chief Commercia.. EVP, Chief Commercial Officer Mar 24 Sell 159.2 27,690 4,408,248 60,941 03/25/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Option 79.02 11,682 923,112 37,722 03/11/22
Durkin Brian L VP, Controller VP, Controller Mar 09 Sell 150 18,628 2,794,200 19,094 03/11/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Mar 01 Sell 148.12 25,000 3,703,000 16,623 03/02/22
Gosebruch Henry O EVP, Chief Strategy.. EVP, Chief Strategy Officer Feb 25 Sell 148.43 15,000 2,226,450 41,623 03/01/22
Michael Robert A. Vice Chairman Vice Chairman Feb 25 Sell 148.32 43,105 6,393,334 37,877 03/01/22
Strom Carrie C SVP & Pres Global Al.. SVP & Pres Global Allerg Aesth Feb 07 Sell 141.17 2,396 338,243 42,499 02/08/22
AUSTIN ROXANNE S Director Director Nov 02 Sell 116.42 71,844 8,364,078 49,284 11/04/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Sell 120 13,080 1,569,600 11,595 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Aug 25 Option 114.36 7,080 809,669 18,675 08/25/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Option 86.26 20,195 1,742,021 52,946 02/24/21
Sorg Elaine K. SVP, US Commercial O.. SVP, US Commercial Operations Feb 24 Sell 105 20,195 2,120,475 32,751 02/24/21
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Option 51.42 51,990 2,673,326 51,990 12/01/20
RICHMOND TIMOTHY J. EVP, Chief HR Office.. EVP, Chief HR Officer Dec 01 Sell 105 51,990 5,458,950 12/01/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Option 24.21 4,800 116,208 118,667 11/12/20
SALEKI-GERHARDT AZITA EVP, Operations EVP, Operations Nov 12 Sell 93.61 4,800 449,328 113,867 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Option 56.87 194,154 11,041,538 512,796 11/12/20
GONZALEZ RICHARD A Chairman of the Boar.. Chairman of the Board and CEO Nov 12 Sell 96.76 231,604 22,410,003 318,642 11/12/20